Categories
Aging Genetics Genomics Longevity

Genetic “Ageotypes” predict health as we age

Stanford’s Michael Snyder has categorized how humans age into different classes called “ageotypes”: metabolic, immune, hepatic and nephrotic.

43 healthy men and women between the ages of 34 and 68 were profiled, with extensive measurements of certain microbes and biological molecules, such as proteins, metabolites and lipids, taken at least five times over two years.

Snyder said that the study enabled the researchers to see clear patterns of how individuals experience aging on a molecular level and help them focus on health-risk factors and find the areas in which they’re most likely to encounter problems in the future.

For example, those who are metabolic agers might be at a higher risk for diabetes or show signs of elevated hemoglobin A1c as they grow older. Immune agers might generate higher levels of inflammatory markers or be more prone to immune-related diseases as they age. The ageotypes are not mutually exclusive. They signify the pathways in which increases in aging biomarkers are most pronounced

Differences in aging between healthy and insulin resistant participants were studied for the first time. Snyder discovered 10 molecules that significantly differed between insulin-sensitive and insulin-resistant people as they age. Many of those markers were involved in immune function and inflammation.

In some people, their markers decreased, at least for a short period, when they changed their behavior. The overall rate at which they aged declined, and in some cases aging markers decreased. This occured in molecules including hemoglobin A1c and creatine, a marker for kidney function, among a small subset of participants.

In that subset, Snyder said, there were individuals who made lifestyle changes to slow their aging rate. Among those who exhibited decreased levels of hemoglobin A1c, many had lost weight, and one made dietary changes. Some who saw a decrease in creatine, indicating improved kidney function, were taking statins. In other cases, exactly why rates of aging markers waned was unclear. For some people, there were no obvious behavioral changes, yet the team still saw a decreased rate of aging along their ageotype pathways. There was also a handful of people that maintained a slower-than-average aging rate throughout the entire study.

Prof Snyder was a speaker at the 2019 ApplySci conference at Stanford.


Join ApplySci at the 13th Wearable Tech + Digital Health + Neurotech Silicon Valley conference on February 11-12, 2020 at Quadrus Sand Hill Road.  Speakers include:  Zhenan Bao, Stanford – Vinod Khosla, Khosla Ventures – Mark Chevillet, Facebook – Shahin Farshchi, Lux Capital – Carla Pugh, Stanford – Nathan Intrator, Tel Aviv University | Neurosteer – Wei Gao, Caltech – Sergiu Pasca, Stanford – Walter Greenleaf, Stanford – Sheng Xu, UC San Diego – Dror Ben-Zeev, University of Washington – Mikael Eliasson, Roche  – Unity Stoakes, StartUp Health – Garth Smith, Ontario Brain Institute – Erika Ross, Abbott Neuromodulation

Categories
Genetics

Genetic manipulation in neuroscience, reproductive medicine, cancer

http://www.technologyreview.com/news/508981/its-all-about-the-genes-and-the-brain-machines/

MIT’s Technology Review reports advances in genome sequencing in several areas.  Most applicable to ApplySci is the melding of mind and machine.  Their coverage follows:

“The melding of mind and machine was also big this year. Scientists in Winston-Salem, North Carolina, demonstrated that a brain implant could replace some cognitive function in primates, which could one day help people with brain damage. On the flip side, two research groups published the first accounts of quadriplegic people using brain implants to control robotic limbs. The implants recorded the participants’ intentions to move, which were translated by a computer into instructions for a robotic arm. The idea is that one day people with severe paralysis or amputations could use such neural prosthetics at home to help with the tasks of daily life.

Brain electronics were also implanted into Alzheimer’s patients this year in an attempt to slow a disease that has so far evaded pharmaceutical treatment.  The urgency for treatment is growing, but the community still doesn’t know what sets into motion the cascade of molecular events that robs people of their memory and thinking skills. With better diagnostic tools and the discovery that there are warnings decades before symptoms, scientists are turning to treating patients with a genetic predisposition for the disease before they start having symptoms. Perhaps this will be the key to treatments in future years. ”

MIT Technology Review, December 24, 2012